Clinical trial
Enhancing the Secondary Prevention of Coronary Artery Disease
NCT00175240 · University of Alberta, Other · Completed
Key facts
| NCT number | NCT00175240 |
|---|---|
| Title | Enhancing the Secondary Prevention of Coronary Artery Disease |
| Official title | Enhancing the Use of Secondary Prevention Strategies in Patients With Coronary Artery Disease (The ESP-CAD Study) |
| Lead sponsor | University of Alberta, Other |
| Collaborators | Heart and Stroke Foundation of Canada Alberta Heritage Foundation for Medical Research Pfizer Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Coronary Disease, Ischemic Heart Disease |
| Intervention type | Behavioral |
| Interventions | Evidence summaries endorsed by local opinion leaders |
| Enrollment | 480 |
| Start date | Mar 1, 2005 |
| Primary completion | Aug 1, 2011 |
| Completion | Jul 1, 2015 |
| First posted | Sep 15, 2005 |
| Last update posted | Jul 28, 2015 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: